ClinicalTrials.gg
CompletedNCT00991068Updated Mar 16, 2012

Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

A Phase 2 interventional study of Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch in Carpal Tunnel Syndrome, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.

Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing lidocaine in Carpal Tunnel Syndrome — 1 open to participants now, 1 under way, none of them phase 3. Lidocaine · Carpal Tunnel Syndrome.

Enrollment
10th of 10
24 · median 51
Started
2009
the only one that year
Phase 2
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
1 of 10
ZARS Pharma Inc.

Among the 10 studies testing lidocaine in Carpal Tunnel Syndrome, this one is the 10th largest by enrollment, is the only one that started in 2009, is the only one in phase 2, and was the 3rd registered.

Carpal Tunnel Syndrome

589 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.

Browse Carpal Tunnel Syndrome studies →

Open to participants now

1 of the 10 studies testing lidocaine in Carpal Tunnel Syndrome is open now. Recruiting first, the newest first:

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 73 Carpal Tunnel Syndrome studies recruiting now, 27 (37%) set no upper age limit and 37 (51%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing lidocaine in Carpal Tunnel Syndrome, or all of them as a file.
02

Study summary

The purpose of the study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate carpal tunnel syndrome.

Read the detailed description

ZARS Pharma, Inc. has developed Synera® (lidocaine 70 mg and tetracaine 70 mg topical patch), a drug delivery patch that utilizes controlled heat to enhance the delivery of a local anesthetic formulation consisting of a eutectic mixture of lidocaine and tetracaine. Synera was approved by the Food and Drug Administration (FDA) on June 23, 2005 and is indicated for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodesiccation, and shave biopsy of skin lesions.

The purpose of this single center, 2-week open-label pilot study is to explore the potential usefulness of Synera for the treatment of pain associated with mild to moderate CTS.

03

Conditions studied

  • Carpal Tunnel Syndrome

Keywords

  • Pain
  • Mild to moderate Carpal Tunnel Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pain associated with mild to moderate carpal tunnel syndrome in a single wrist
  • Have recent (within 3 months) electrodiagnostic evidence of carpal tunnel syndrome (CTS)

Exclusion criteria

Exclusion Criteria:

  • Have bilateral carpal tunnel syndrome
  • Have another peripheral neuropathy in the affected limb
  • Have had an injection into the carpal tunnel within 8 weeks
  • Have had surgical release of the target wrist within previous 6 months
  • Have electrodiagnostic evidence of severe CTS

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Synera

    Synera topical patch

    Drug: Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch

Interventions

  • DrugSynera (lidocaine 70 mg and tetracaine 70 mg) topical patch

    Drug page: Lidocaine

    Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Time frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal

Secondary outcomes

  1. Pain interference with activities (general, normal work, sleep)

    Time frame: Screening/Day 1, Day 8, and Day 15 or early withdrawal

07

Study locations

1 site
  • International Clinical Research Institute
    Overland Park, Kansas 66211, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2009
First posted
Oct 7, 2009
Start
Sep 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results delay requested
Mar 14, 2012
Last update
Mar 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00991068
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Oct 7, 2009
Start date
Sep 2009
Primary completion
Mar 2010
Completion
Mar 2010
Last update
Mar 16, 2012

Study contacts

Srinivas Nalamachu, MD
principal investigator · International Clinical Research Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion